LIVANOVA PLC(NASDAQ:LIVN) stock News

LIVN Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Yahoo Finance

Jefferies Reiterates a Buy Rating on LivaNova PLC (LIVN) With a $79 PT

14 days ago - By: LivaNova PLC

LivaNova to Announce Second-Quarter 2025 Results

2 months ago - By: LivaNova PLC

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

3 months ago - By: Benzinga - Mentions: XPER EMR BLZE ERII ...

Earnings Scheduled For May 7, 2025

2 months ago - By: LivaNova PLC

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

2 months ago - By: LivaNova PLC

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

2 months ago - By: Yahoo Finance - Mentions: UBS KR HPQ DB ...

MongoDB and Asana downgraded: Wall Street's top analyst calls

2 months ago - By: LivaNova PLC

LivaNova to Present at the Jefferies Global Healthcare Conference

3 months ago - By: LivaNova PLC

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

3 months ago - By: LivaNova PLC

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

3 months ago - By: Zacks Investment Research - Mentions: MASI

Masimo (MASI) Q1 Earnings and Revenues Surpass Estimates

3 months ago - By: Zacks Investment Research - Mentions: DXCM

DexCom (DXCM) Q1 Earnings Miss Estimates

3 months ago - By: Yahoo Finance - Mentions: TXN EWTX GPCR IGT ...

Jim Cramer Applauds Texas Instruments (TXN): “Put Up Terrific Numbers”

3 months ago - By: Yahoo Finance - Mentions: PUK ET KMI NVDA ...

Is LivaNova PLC (LIVN) the Best Undervalued UK Stock to Buy Right Now?

3 months ago - By: Yahoo Finance - Mentions: PM MCK UL JHG ...

Is Philip Morris International Inc. (PM) the Best Dividend Paying Stock According to Hedge Funds?

3 months ago - By: Yahoo Finance - Mentions: UL JHG AZN NOW ...

LivaNova PLC (LIVN): Among the Best UK Stocks to Buy According to Billionaires

4 months ago - By: LivaNova PLC

LivaNova to Announce First-Quarter 2025 Results

5 months ago - By: LivaNova PLC

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

5 months ago - By: LivaNova PLC

LivaNova to Present at the Barclays Global Healthcare Conference

6 months ago - By: LivaNova PLC

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

7 months ago - By: LivaNova PLC

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

5 months ago - By: Benzinga - Mentions: OUT HURN DNUT SRE ...

Earnings Scheduled For February 25, 2025

7 months ago - By: LivaNova PLC

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

8 months ago - By: LivaNova PLC

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

8 months ago - By: LivaNova PLC

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

8 months ago - By: LivaNova PLC

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

9 months ago - By: LivaNova PLC

LivaNova Reports Third-Quarter 2024 Results

10 months ago - By: LivaNova PLC

LivaNova Appoints Susan Podlogar as a New Director

10 months ago - By: LivaNova PLC

LIVANOVA PLC (LIVN) Stock News

LIVN Latest News, Press Relases and Analysis

Jefferies Reiterates a Buy Rating on LivaNova PLC (LIVN) With a $79 PT

LivaNova to Announce Second-Quarter 2025 Results

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

Earnings Scheduled For May 7, 2025

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

MongoDB and Asana downgraded: Wall Street's top analyst calls

LivaNova to Present at the Jefferies Global Healthcare Conference

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

Masimo (MASI) Q1 Earnings and Revenues Surpass Estimates

DexCom (DXCM) Q1 Earnings Miss Estimates

Jim Cramer Applauds Texas Instruments (TXN): “Put Up Terrific Numbers”

Is LivaNova PLC (LIVN) the Best Undervalued UK Stock to Buy Right Now?

Is Philip Morris International Inc. (PM) the Best Dividend Paying Stock According to Hedge Funds?

LivaNova PLC (LIVN): Among the Best UK Stocks to Buy According to Billionaires

LivaNova to Announce First-Quarter 2025 Results

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LivaNova to Present at the Barclays Global Healthcare Conference

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

Earnings Scheduled For February 25, 2025

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova Reports Third-Quarter 2024 Results

LivaNova Appoints Susan Podlogar as a New Director

LivaNova to Announce Third-Quarter 2024 Results